MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing
A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 5850 participants.
Also called NCT02006069
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 5,850 participants
- Sponsor
- Registry
-
NCT02006069
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Canada, China, Colombia, Denmark, Finland, France, Germany, Greece, India, Israel, Italy, Lebanon, Malaysia, Malta, Netherlands, Poland, Portugal, Puerto Rico, Saudi Arabia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT02006069. Randomized; single masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2021-05-30 (actual). Results posted on 2023-05-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing
- Acronym
- MORE CRT MPP
- Condition
- Heart Failure
- Intervention (Device)
- MPP
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct02006069- Content hash
02e075e5f4ad2274402a7e620deabc74c909fadfcc741c8d6513ea87f2492684